A patient who was previously taking venlafaxine 150 mg orally daily and has been off it for eight months wants to restart therapy; should the medication be restarted at the same dose?

Restarting Venlafaxine After 8-Month Discontinuation

No, do not restart at 150 mg daily—begin with a lower starting dose of 37.5-75 mg daily and titrate upward over 2-4 weeks to the target dose of 150 mg. 1, 2

Rationale for Dose Titration

After 8 months off venlafaxine, the patient should be treated as if initiating therapy for the first time. The standard starting dose for venlafaxine is 37.5 mg once or twice daily, with increases of 75 mg each week as tolerated, up to the therapeutic target. 1

• Venlafaxine requires 2-4 weeks to titrate to an efficacious dosage of 150-225 mg/day to minimize adverse effects and improve tolerability 1
• Starting at the full 150 mg dose increases the risk of dose-dependent adverse effects including nausea, dizziness, headache, insomnia, and blood pressure elevation 1, 2
• The FDA label explicitly recommends gradual dose escalation rather than abrupt initiation at higher doses 2

Recommended Titration Schedule

Week 1-2: Start venlafaxine 37.5 mg daily (or 37.5 mg twice daily for immediate-release formulation) 1

Week 2-3: Increase to 75 mg daily if tolerated 1

Week 3-4: Increase to 150 mg daily (the patient's previous maintenance dose) 1

• Extended-release formulations permit once-daily dosing, while immediate-release may require twice- or thrice-daily dosing due to shorter half-life 1
• Monitor for tolerability at each dose increment before advancing 2

Critical Safety Considerations

Blood pressure monitoring is essential during venlafaxine titration and maintenance, as the medication causes dose-dependent sustained hypertension in some patients 1, 2

• Pre-existing hypertension should be controlled before restarting venlafaxine 2
• Regular blood pressure monitoring is recommended throughout treatment 2
• In older adults (≥60 years), 6.5% develop elevated BP during treatment, with higher rates at doses ≥225 mg/day 3
• Orthostatic hypotension also occurs in approximately 20% of older adults treated with venlafaxine, increasing fall risk 3

Withdrawal syndrome risk: The patient's 8-month gap means withdrawal is not a current concern, but venlafaxine is associated with significant discontinuation symptoms if stopped abruptly in the future 1, 4, 5

• Venlafaxine has a higher intensity withdrawal syndrome compared to SSRIs 4
• Symptoms can occur within hours of missed doses and may include dizziness, nausea, sensory disturbances, anxiety, and agitation 1, 4, 5
• Future discontinuation should involve gradual dose tapering 2, 4

Monitoring for Efficacy

An adequate trial requires 4-6 weeks at the target therapeutic dose to assess response 1

• Typically 2-4 weeks are needed just for titration to 150-225 mg/day 1
• Early response (≥20% symptom reduction by week 2) predicts higher likelihood of eventual remission 6
• If inadequate response after 6-8 weeks at therapeutic dose, consider dose adjustment up to maximum 225 mg/day (or 375 mg/day for immediate-release in severely depressed patients) 1, 2

Common Pitfalls to Avoid

Do not assume previous tolerance guarantees current tolerance. After 8 months off medication, the patient's physiologic adaptation to venlafaxine has resolved, necessitating re-titration 2

Do not skip baseline assessments. Before restarting, evaluate:

• Current blood pressure (pre-existing hypertension requires control first) 2
• Cardiac history (venlafaxine can cause cardiac conduction abnormalities) 1
• Concurrent medications (particularly other serotonergic agents due to serotonin syndrome risk) 1, 2
• Renal and hepatic function (dose reduction required if impaired) 2

Do not combine with MAOIs or start within 14 days of MAOI discontinuation due to potentially fatal serotonin syndrome 2